European Commission approves NewAmsterdam Pharma’s Ubeslo and Evlarco
TradingView News reports the European Commission approved NewAmsterdam Pharma’s Ubeslo and Evlarco.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
European Commission approves NewAmsterdam/Menarini obicetrapib therapies
European Commission approval granted for NewAmsterdam Pharma’s obicetrapib monotherapy (Ubeslo®) and obicetrapib plus ezetimibe fixed-dose combination (Evlarco®), per TradingView News.
European Commission approves NewAmsterdam’s Ubeslo and Evlarco in EU
The European Commission approved Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination) for NewAmsterdam Pharma and Menarini, supported by Phase 3 BROADWAY, BROOKLYN and TANDEM trials showing LDL-C reductions and favorable tolerability.